Low Dose Naltrexone (LDN)

What is Low Dose Naltrexone?

Low Dose Naltrexone is an unusual compound in the biohacker space — it's the same molecule as naltrexone, an FDA-approved opioid antagonist at 50 mg, but used at 1-5 mg with a completely different pharmacological effect. The dose is not just smaller — the mechanism actually changes. This is one of the most clinically interesting examples of dose-dependent mechanism shift in pharmacology.

At 50 mg (the approved dose), naltrexone continuously blocks opioid receptors, preventing opioids from producing their effects. This is appropriate for treating opioid and alcohol use disorder — you want sustained receptor blockade. At 1-5 mg taken at bedtime, naltrexone briefly blocks opioid receptors for 4-6 hours overnight, then clears. The body responds to this brief blockade with a compensatory upregulation of endogenous endorphins and enkephalins — natural opioid peptides that have immune-modulating properties beyond analgesia. Additionally, at low doses, naltrexone antagonizes Toll-like receptor 4 (TLR4) on glial cells — microglia in the brain and macrophages in the periphery — reducing neuroinflammation and systemic inflammatory cytokine production.

The clinical evidence is meaningful and growing. An open-label pilot in adults with active Crohn's disease saw most patients respond and about two-thirds reach remission, and a follow-up randomized, placebo-controlled trial in children with moderate-to-severe Crohn's found LDN well tolerated with significantly reduced disease-activity scores. An MS trial showed LDN improved quality of life and reduced pain. Fibromyalgia RCTs showed significant pain and symptom reduction. The long COVID application is newer and the evidence is primarily observational, but LDN has emerged as one of the most-discussed interventions in long COVID communities with real clinical experience behind it.

For the PepperLedger audience — which includes users with MCAS, long COVID, chronic inflammatory conditions, and people using immune-modulating compounds like Thymosin Alpha-1 and VIP — LDN is a mechanistically complementary compound. It's not a peptide, but it's firmly in the same immune-modulating space and is used by many of the same people. The prescription barrier is real but increasingly manageable through telemedicine men's/women's health and longevity-focused practices.

How it works

The Rebound Endorphin Mechanism

Naltrexone at 50 mg continuously occupies opioid receptors. At 1-5 mg taken at night, the drug occupies opioid receptors for approximately 4-6 hours (consistent with its half-life), then clears. The body detects the brief receptor blockade and compensates by upregulating endogenous opioid production — endorphins, enkephalins, and dynorphins — along with their receptors. This rebound upregulation produces elevated endogenous opioid signaling beyond the naltrexone's clearance. Endogenous opioids have immune-modulating properties: they regulate NK cell activity, T-cell proliferation, and inflammatory cytokine balance. The net effect is immune modulation via endorphin upregulation.

TLR4 Antagonism — Glial Cell Neuroinflammation

Toll-like receptor 4 (TLR4) is expressed on microglia (the brain's immune cells) and peripheral macrophages. TLR4 recognizes danger signals and triggers pro-inflammatory cytokine production — TNF-α, IL-1β, IL-6. Glial TLR4 activation drives neuroinflammation, which is increasingly recognized as a driver of chronic pain, fatigue, brain fog, and multiple neurological conditions. Naltrexone (and its active metabolite 6-β-naltrexol) antagonizes TLR4 at low concentrations — reducing microglial activation and neuroinflammatory cytokine production. This TLR4 mechanism is the basis for LDN's effects on fibromyalgia, MS pain, and cognitive symptoms of long COVID and chronic fatigue.

Why Bedtime Dosing Matters

Natural endorphin production peaks during the early nighttime hours (roughly 2-4 AM). Taking LDN at bedtime (10 PM - midnight) times the opioid receptor blockade to coincide with the natural endorphin production peak — maximizing the rebound upregulation effect when the body would naturally be producing the most endorphins anyway. This timing is not arbitrary — it's mechanistically informed.

What the research shows

What the community reports

LDN has one of the most vocal and organized patient communities of any off-label compound — the LDN Research Trust has collected thousands of patient reports and has been instrumental in funding clinical trials. The long COVID community has made LDN one of its most-discussed interventions. This gives LDN community data that is more systematically collected than most research chemicals.

Common misconceptions